Connect with us

Technology

Powerful Lyme Disease Awareness PSA Featuring Christopher Meloni Illuminates Times Square

Published

on

Global Lyme Alliance (GLA), a leading nonprofit, produces chronic Lyme PSA with generous sponsorship from QuidelOrtho to ensure the broad visibility of this crucial message.

STAMFORD, Conn., Oct. 17, 2023 /PRNewswire/ — In an inspiring and emotional display of solidarity for Lyme disease awareness, a striking public service announcement (PSA) has taken center stage in the heart of New York City’s Times Square. The PSA, is a poignant call to action, shedding light on chronic Lyme disease.

 

“We hope this PSA will serve as a tool to bring awareness to the often underestimated magnitude of Lyme disease.”

The video, which can be viewed here: https://youtu.be/989Q5yeXTKQ?si=b3nQUMHmIXMr5IRj has garnered attention for its raw authenticity and honest narrative about what it’s like to have chronic Lyme disease. Directed by Erich Bergen, the PSA features Global Lyme Alliance (GLA) celebrity ambassador and actor Christopher Meloni, whose family has been impacted by Lyme disease.

The PSA is being displayed on one of Times Square’s iconic electronic billboards through December 31, 2023, ensuring millions of residents and tourists alike have the opportunity to see and engage with its powerful message. The decision to feature the PSA in Times Square reflects a collective effort to bring awareness to chronic Lyme disease. GLA, in partnership with QuidelOrtho, which proudly sponsored this impactful initiative, believes that by showcasing the PSA on chronic Lyme disease in such a prominent location, they can contribute to breaking down the barriers surrounding the stigma that comes from chronic Lyme disease and empower individuals to seek help without fear of judgment.

“Times Square has long been a symbol of hope, dreams, and unity,” said Laura MacNeill, CEO of GLA. “We hope this PSA will serve as a tool to bring awareness to the often underestimated magnitude of Lyme disease. We encourage everyone to watch, share, and join us in supporting Lyme disease awareness, so that we can create real change for those who have been suffering and for those who have not been affected yet.”

GLA invites the public to engage in the conversation on social media using the hashtag #ChronicLymeIsReal and posting about the PSA if they see it in Times Square by tagging GLA. By sharing stories, words of encouragement, and resources for Lyme disease support, individuals can contribute to building a supportive community dedicated to bringing awareness to this insidious disease.

About Lyme disease:
Lyme disease is a global health crisis. It is a much bigger problem than most people realize, impacting millions around the world. According to the Centers for Disease Control and Prevention, Lyme disease is a growing epidemic, with more than 476,000 reported new cases each year in the United States, and while many are treated successfully, far too many are not. There are millions out there suffering from a chronic form of this illness with debilitating symptoms that do not go away. 

About Global Lyme Alliance:
The mission of Global Lyme Alliance is to cure Lyme and other tick-borne diseases through innovative research, awareness, and empowering the patient voice. GLA has gained national prominence for funding some of the most urgent and promising research in the field by awarding over $17 million to our research program to date. GLA supports patients through every step in their journey, from finding a Lyme-treating physician to a peer-to-peer mentor program and a wealth of resources and information on its website. GLA also offers an ambassador program for volunteers to raise awareness through education, create fundraising events in their area, or collaborate to advance GLA’s mission. Visit us on social media or learn more at GLA.org.

About QuidelOrtho Corporation:
QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day. 

Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic. So that patients, clinicians and health officials can spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence.

Building upon its many years of groundbreaking innovation, QuidelOrtho continues to partner with customers across the healthcare continuum and around the globe to forge a new diagnostic frontier. One where insights and solutions know no bounds, expertise seamlessly connects and a more informed path is illuminated for each of us.

QuidelOrtho is advancing diagnostics to power a healthier future.

For more information, please visit www.quidelortho.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/powerful-lyme-disease-awareness-psa-featuring-christopher-meloni-illuminates-times-square-301959586.html

SOURCE Global Lyme Alliance

Continue Reading

Technology

Sophia Space and MIT Lincoln Laboratory Announce Research Collaboration on Space-Based Weather Modeling

Published

on

By

CRADA and related SpaceWERX Phase I research will explore space-based computing approaches for weather-modeling applications

PASADENA, Calif., Oct. 20, 2026 /PRNewswire/ — Sophia Space today announced a new Cooperative Research and Development Agreement (CRADA) with MIT Lincoln Laboratory to investigate how space-based computing approaches could support high-resolution weather-modeling research for remote operating environments.

The collaboration combines MIT Lincoln Laboratory’s weather-modeling research expertise with Sophia Space’s edge-compute concepts. The effort will explore whether distributed computing can support more timely environmental information for planning and decision-support applications.

Under the agreement, MIT Lincoln Laboratory will contribute weather-modeling research expertise, including the identification of modeling configurations, parameters, and data sources for evaluation. The team will develop representative test data and assess weather-model performace against defined research metrics using frameworks compatible with Sophia Space’s initial hardware configurations.

Sophia Space will provide the AI-inference compute environment for evaluating representative weather-model workloads, including terrestrial and potential space-based computing configurations. The organizations will explore high-level system and service architectures that may inform future research into space-based computing applications.

Sophia Space and MIT Lincoln Laboratory are also pursuing related work under Department of the Air Force STTR Topic SF25D-T1201 through the SpaceWERX Futures Series: Adaptive and Intelligent Space Challenge. The related effort examines technologies relevant to autonomous, resilient, and networked space-system operations.

“This partnership reflects our conviction that space-based computing infrastructure should be developed through rigorous collaboration between commercial innovators and world-class research institutions,” said Rob DeMillo, Co-founder and CEO of Sophia Space. “MIT Lincoln Laboratory brings unmatched weather sensing, forecasting and decision-support research expertise, and together we will explore the potential application of space-based computing to weather-modeling research.”

The collaboration aligns with Sophia Space’s research interests in edge-compute architectures, distributed processing, and sensor fusion integration for environments.

“Timely weather information is critical for operations in remote and contested environments,” said Dr. Timothy Bonin, Assistant Group Leader of the Air Traffic Control & Weather Systems Group at MIT Lincoln Laboratory. “This collaboration allows us to explore how space-based computing can help process satellite observations and other environmental data closer to the point of collection, while assessing potential impacts on communications demands and information-delivery timelines.”

About Sophia Space Inc.
Sophia Space is building the future of orbital computing and in-space data centers. Its modular TILE (Thermal-Integrated LEO Edge) technology enables passive computing alongside in-situ data processing, AI acceleration, and edge computing for satellites, defense systems, and commercial space stations—dramatically reducing latency and delivering actionable insights where and when they are needed. Learn more at www.sophia.space.

About MIT Lincoln Laboratory
MIT Lincoln Laboratory is a federally funded research and development (R&D) center chartered to apply advanced technology to problems of national security. Since 1951, the Laboratory has developed technology that has transformed the activities of the defense, scientific, and industry communities. Its mission focuses on long-term technology development as well as rapid system prototyping and demonstration. Through several mechanisms, it facilitates partnerships with companies to advance R&D and increase U.S. technical competitiveness. Learn more at www.ll.mit.edu.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-space-and-mit-lincoln-laboratory-announce-research-collaboration-on-space-based-weather-modeling-302913439.html

SOURCE Sophia Space

Continue Reading

Technology

Oracle and AstraZeneca Partner to Advance AI-enabled Healthcare Innovation

Published

on

By

Collaboration to connect AstraZeneca’s scientific and therapeutic expertise with Oracle’s real-world data, cloud, AI, and clinical capabilities to accelerate clinical research and bring evidence-driven insights into care workflows to help improve patient care

AUSTIN, Texas and ABU DHABI, UAE, Oct. 20, 2026 /PRNewswire/ — Oracle today announced an agreement with AstraZeneca to explore how AI and real-world data can help clinicians identify eligible patients for clinical trials, accelerate evidence generation, and bring relevant research insights into everyday care. The collaboration is expected to combine AstraZeneca’s scientific and therapeutic expertise with Oracle’s health data, cloud, AI, analytics, and clinical workflow capabilities.

Through a non-binding agreement, the companies plan to explore selected use cases that could improve clinical-trial efficiency and success by leveraging modern applications and AI to help care teams identify eligible patients earlier and easier, resulting in greater access to clinical trials for patients in need and helping to overcome one of the largest obstacles in clinical trials – patient recruitment. Initial disease areas to be explored could include oncology; cardiovascular, renal and metabolic diseases; respiratory and immunology; and rare diseases.

Pascal Soriot, Chief Executive Officer, AstraZeneca said: “This unique collaboration brings leaders in healthcare and AI together at a global scale to accelerate the journey from the discovery of medicine to patient care. Combining AstraZeneca’s world class science with Oracle’s deep data and technology expertise, we can help clinicians identify patients sooner, optimize clinical trials, and generate evidence continuously across the lifecycle of a medicine.”

“Some of the most important opportunities for AI are in healthcare, where better use of data can help turn scientific innovation into better outcomes for patients,” noted Mike Sicilia, chief executive officer, Oracle. “By bringing AstraZeneca’s scientific expertise together with Oracle’s data, cloud, AI, and healthcare capabilities, we have an opportunity to help accelerate research, connect more patients to clinical trials, and ultimately bring relevant insights into care faster.”

Connecting Research and Care

Anne-Claire Gerbaldi, Chief Digital, Data and AI Officer, AstraZeneca, added: “Too many patients are diagnosed late or face a long journey to get the care they need. To build the next decade of medicine, we aim to harness AI to connect learnings across science, clinical trials, and everyday care, generating insights that continuously strengthen research, accelerate innovation, and enhance patient outcomes. Bringing together the unique capabilities of Oracle and AstraZeneca, we believe we can support smarter clinical trials, strengthen safety monitoring, and help ensure patients are diagnosed sooner and receive the right care.”

Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences, said: “Healthcare progress depends on shortening the distance between scientific insight and the decisions clinicians make every day. AstraZeneca brings deep scientific and therapeutic expertise, and Oracle will deliver the secure data, cloud, AI, and clinical workflow capabilities. This collaboration has the potential to help health systems identify eligible patients sooner, broaden access to clinical trials, and generate evidence that supports the next decision, all under the governance of the health systems delivering care.”

AstraZeneca and Oracle intend to explore a continuous learning model in which insights from clinical research and routine care help inform future study design, safety monitoring, and patient care. The companies plan to establish shared governance, reusable technical components, and agreed outcome measures to assess results and determine whether successful approaches could extend across disease areas and geographies.

About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit www.oracle.com.

Trademarks
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company – ushering in the new era of cloud computing.

View original content to download multimedia:https://www.prnewswire.com/news-releases/oracle-and-astrazeneca-partner-to-advance-ai-enabled-healthcare-innovation-302913441.html

SOURCE Oracle

Continue Reading

Technology

Loyyal Unveils Perxi AI Business Suite to Help SMEs Run Their Business on WhatsApp

Published

on

By

Branded AI assistant brings everyday business activities into messaging channels, reducing the need for separate software and specialist teams

DUBAI, UAE, Oct. 20, 2026 /PRNewswire/ — Loyyal today unveiled the Perxi AI Business Suite, enabling small and medium enterprises (SMEs) to manage everyday business activities through WhatsApp. Building on its introduction as a loyalty assistant, Perxi brings commerce, customer engagement and business management into one conversational interface, with capabilities including ordering, customer service and loyalty.

The suite helps SMEs and direct-to-consumer brands manage these activities without purchasing separate ordering systems, customer relationship management software or support tools. Its conversational approach reduces the need to hire specialists or train employees to operate multiple systems.

“Small business owners should be able to focus on growth without assembling a collection of software tools,” said Ashish Kumar Singh, Founder and CEO of Loyyal.

“Perxi brings everyday business capabilities into WhatsApp under each business’s own brand. We want to make these tools affordable and accessible while helping businesses retain greater control over their customer relationships, data and decisions.”

Perxi provides the underlying technology, while each business launches its assistant under its own brand name. Customers engage directly with the business they recognise, rather than entering a separate Perxi marketplace.

Customers can place orders, ask questions, receive assistance and access rewards within a familiar conversation. There is no additional branded application to install or separate login to remember. This approach is designed to appeal to younger consumers accustomed to discovering and interacting with brands through mobile messaging.

Beyond WhatsApp, Perxi can be deployed across messaging channels suited to each business and market, including Instagram, WeChat and KakaoTalk.
Multilingual capabilities enable businesses to serve customers in their preferred languages, supporting brands operating beyond English and those engaging diverse communities.

As conversational commerce and AI assistants become more prominent, SMEs face growing expectations for convenient, responsive interactions. Bringing business services into messaging channels offers a way to meet those expectations while building direct customer relationships.

Marketplaces and aggregators offer a fast route to market, but access to customer information and engagement opportunities varies. Perxi helps businesses establish a direct channel and gain insights from their own customer conversations and transactions.

These insights can inform service improvements, personalised engagement and retention, while reducing dependence on intermediaries for customer access.

Pricing is designed to remain simple and affordable. Loyyal plans further services under the same umbrella.

Perxi will return to exhibit at Dubai AI Festival on October 26–27, 2026, at Dubai World Trade Centre.

About Loyyal

Loyyal is a US-born, UAE-based enterprise technology company helping businesses turn loyalty and customer engagement into growth and revenue. Combining patented blockchain technology with AI, its modular portfolio spans loyalty management, rewards, points exchange, offers, gift cards, gamification and conversational business assistants.

Media Contact

Marketingdepartment@loyyal.com

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/loyyal-unveils-perxi-ai-business-suite-to-help-smes-run-their-business-on-whatsapp-302913064.html

Continue Reading

Trending